[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE0403006D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0403006D0
SE0403006D0 SE0403006A SE0403006A SE0403006D0 SE 0403006 D0 SE0403006 D0 SE 0403006D0 SE 0403006 A SE0403006 A SE 0403006A SE 0403006 A SE0403006 A SE 0403006A SE 0403006 D0 SE0403006 D0 SE 0403006D0
Authority
SE
Sweden
Prior art keywords
sup
compounds
new compounds
prophylaxis
obesity
Prior art date
Application number
SE0403006A
Other languages
English (en)
Inventor
Gary Johansson
Katarina Beierlein
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to SE0403006A priority Critical patent/SE0403006D0/sv
Publication of SE0403006D0 publication Critical patent/SE0403006D0/sv
Priority to US11/296,928 priority patent/US20060142269A1/en
Priority to PCT/SE2005/001885 priority patent/WO2006062481A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0403006A 2004-12-09 2004-12-09 New compounds SE0403006D0 (sv)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0403006A SE0403006D0 (sv) 2004-12-09 2004-12-09 New compounds
US11/296,928 US20060142269A1 (en) 2004-12-09 2005-12-08 New compounds
PCT/SE2005/001885 WO2006062481A1 (en) 2004-12-09 2005-12-09 New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0403006A SE0403006D0 (sv) 2004-12-09 2004-12-09 New compounds

Publications (1)

Publication Number Publication Date
SE0403006D0 true SE0403006D0 (sv) 2004-12-09

Family

ID=33550628

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0403006A SE0403006D0 (sv) 2004-12-09 2004-12-09 New compounds

Country Status (2)

Country Link
US (1) US20060142269A1 (sv)
SE (1) SE0403006D0 (sv)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
CA2735184C (en) 2008-09-11 2013-05-28 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
RS52903B (en) * 2009-03-11 2014-02-28 Pfizer Inc BENZOFURANIL DERIVATIVES FOR USE AS GLUCOKINASE INHIBITORS
ES2613664T3 (es) * 2009-10-26 2017-05-25 Signal Pharmaceuticals, Llc Procedimientos de síntesis y purificación de compuestos de heteroarilo
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
SG187103A1 (en) 2010-07-16 2013-02-28 Abbvie Inc Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
MX344148B (es) 2010-07-16 2016-12-07 Abbvie Ireland Unlimited Co Proceso para la preparacion de compuestos antivirales.
WO2013059396A2 (en) 2011-10-19 2013-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
BR112014020786A2 (pt) 2012-02-24 2020-10-27 Signal Pharmaceuticals, Llc método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9428509B2 (en) 2013-01-16 2016-08-30 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用tor激酶抑制劑組合療法以治療癌症之方法
AU2014254050B2 (en) 2013-04-17 2018-10-04 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
MX2015014590A (es) 2013-04-17 2016-03-03 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
MX2015014455A (es) 2013-04-17 2016-07-21 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
MX2015015880A (es) 2013-05-29 2016-05-31 Signal Pharm Llc Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida del mismo y metodos de su uso.
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
AU2016353004B2 (en) * 2015-11-11 2020-11-05 Ambient Photonics, Inc. Benzofuran derivatives for the treatment of CNS and other disorders
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗

Also Published As

Publication number Publication date
US20060142269A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
SE0403006D0 (sv) New compounds
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
GEP20125565B (en) Lactam compounds and their pharmaceutical use
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE384058T1 (de) Thiazolderivate
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
GB0625648D0 (en) Compounds
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
SE0300119D0 (sv) Novel compounds
EA201070423A1 (ru) Диарильные соединения оксадиазолов
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200745122A (en) New compounds I
TW200745081A (en) Compounds
TW200505865A (en) Compounds useful for the treatment of diseases
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EA200601462A1 (ru) Соединения для лечения заболеваний
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2077719A4 (en) BETA-SECRETASE PIPERIDINE AND PYRROLIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE